Documents

Q1 FY 2027 saw 26% revenue growth and upgraded FY 2027 outlook to mid-teens, led by U.S. generics.

Steady growth in FY 2026 sets the stage for margin improvement and double-digit growth in FY 2027.

Q3 revenue up 11% YoY; U.S. and ROW growth strong, India to match market by next fiscal.

Q2 saw 16% revenue growth, margin expansion, and a strategic U.S. branded entry via acquisition.

Q1 delivered 10% revenue growth, margin gains, and robust U.S./ROW outlook amid India challenges.

Q4 FY25 delivered double-digit revenue growth, strong U.S. generics, and higher R&D investment.

Q3 FY25 saw 4% revenue growth, 23% net profit drop, and strong US/Animal Health gains.

Q2 delivered solid growth in key segments, with H2 outlook boosted by robust new launches.

Q1 revenue up 5%, US generics up 18%, API down 15%, margins stable, supply issues easing.